Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics, Inc. is a healthcare company focused on medical technology for the treatment of dentofacial abnormalities, obstructive sleep apnea, and snoring in adults. The company’s core offering, The Vivos Method, is a non-invasive, non-surgical, and non-pharmaceutical treatment approach that uses a multidisciplinary model for these conditions. It also provides the VivoScore Program, which combines screening with at-home sleep testing for both adults and children. Vivos Therapeutics markets its appliances, related treatments, and services to licensed professionals, with a primary focus on general dentists in the United States and Canada. Founded in 2016 and based in Littleton, Colorado, the company previously operated under the name Vivos BioTechnologies, Inc. before adopting its current name in March 2018. Its common stock trades on the NASDAQ exchange under the symbol VVOS.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-VVOS
$0.57
39.2% Upside
Undervalued
$2.12
416.4% Upside
Bargain
Weak
0.0%
August 19, 2026
-0.2x
-5.0x
0.3x
5.713 M
15.723 M
68.7%
87.3%
-20.2
78.9%
Valuation • Fair Value

Vivos Therapeutics Inc (NASDAQ-VVOS) Fair Value by Valuation Model

Compare the primary fair value estimate for Vivos Therapeutics Inc (NASDAQ-VVOS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.57

Estimated upside of 39.2% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.57

Comparable-company valuation reference.

Analyst Price Target

$2.12

Analysts imply upside of 416.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Vivos Therapeutics Inc (NASDAQ-VVOS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Vivos Therapeutics Inc (NASDAQ-VVOS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

19.568 M

Current operating scale indicator.

Revenue Forecast

24.141 M

Forward revenue estimate.

EBITDA

-21.005 M

Current operating profitability reference.

EBITDA Forecast

-20.115 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Vivos Therapeutics Inc (NASDAQ-VVOS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Vivos Therapeutics Inc (NASDAQ-VVOS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

-3.05

No elevated caution signal from this screen.

Altman Z-Score

-20.2

Lower score that deserves closer risk review.

FCF / Net Income

78.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Vivos Therapeutics Inc (NASDAQ-VVOS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Vivos Therapeutics Inc (NASDAQ-VVOS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 19, 2026

Days to Earnings

29

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Vivos Therapeutics Inc (NASDAQ-VVOS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Vivos Therapeutics Inc (NASDAQ-VVOS) Stock Forecast & Technical Outlook

Review Vivos Therapeutics Inc (NASDAQ-VVOS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Vivos Therapeutics Inc (NASDAQ-VVOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Vivos Therapeutics Inc (NASDAQ-VVOS) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Vivos Therapeutics Inc (NASDAQ-VVOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Vivos Therapeutics Inc (NASDAQ-VVOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Vivos Therapeutics Inc (NASDAQ-VVOS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Vivos Therapeutics Inc (NASDAQ-VVOS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Vivos Therapeutics Inc (NASDAQ-VVOS) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ Fast Investor Answers

Vivos Therapeutics Inc (NASDAQ-VVOS) Stock FAQ

Quick answers about Vivos Therapeutics Inc (NASDAQ-VVOS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.57
Estimated upside 39.2%
Valuation Rating
Undervalued
Estimated upside of 39.2%
Analyst Target
$2.12
Implied upside 416.4%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Vivos Therapeutics Inc (NASDAQ-VVOS) is $0.57. This implies an estimated upside of 39.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 39.2% versus the current market price.

The available analyst price target for Vivos Therapeutics Inc (NASDAQ-VVOS) is $2.12. The analyst target implies estimated upside of 416.4%.

The current financial health read for Vivos Therapeutics Inc (NASDAQ-VVOS) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Vivos Therapeutics Inc (NASDAQ-VVOS) is August 19, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Vivos Therapeutics Inc (NASDAQ-VVOS) is -0.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Vivos Therapeutics Inc is 5.713 M.

The current enterprise value listed for Vivos Therapeutics Inc is 15.723 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Vivos Therapeutics Inc is NASDAQ-VVOS, and the stock is listed on NASDAQ.

Vivos Therapeutics Inc (NASDAQ-VVOS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Vivos Therapeutics Inc is 68.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Vivos Therapeutics Inc is 87.3%. Free float helps investors understand how much of the share base is available for public trading.